Workflow
Zhuhai (688175)
icon
Search documents
高凌信息:通信相关产品暂未进入量子通信领域
人民财讯11月3日电,高凌信息(688175)11月3日在互动平台称,在军用电信网通信设备业务方面,公司 主要产品包括程控交换和分组交换系统设备,以及特种应用产品,应用于军用电信核心网、接入网和其 他特种网络。并融合运营拟态防御技术赋能该领域产品以提高其安全性和竞争力,通信相关产品暂未进 入量子通信领域。网络内容安全业务主要面向通信行业主管部门、电信运营商、公安等客户,为其提供 电信网、互联网、移动互联网诈骗防范为代表的有害信息防范和社会安全应用整体解决方案。公司当前 网络安全产品技术路线和应用场景与量子通信安全不同,后续计划引入量子加密技术进一步增强安全 性。 转自:证券时报 ...
高凌信息11月3日现1笔大宗交易 总成交金额221.05万元 溢价率为-15.02%
Xin Lang Cai Jing· 2025-11-03 10:17
进一步统计,近3个月内该股累计发生11笔大宗交易,合计成交金额为6484.88万元。该股近5个交易日 累计下跌0.44%,主力资金合计净流出94.83万元。 责任编辑:小浪快报 炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 11月3日,高凌信息收跌0.52%,收盘价为24.83元,发生1笔大宗交易,合计成交量10.48万股,成交金 额221.05万元。 第1笔成交价格为21.10元,成交10.48万股,成交金额221.05万元,溢价率为-15.02%,买方营业部为华 创证券有限责任公司北京裕民路证券营业部,卖方营业部为华金证券股份有限公司广东省横琴粤澳深度 合作区分公司。 ...
高凌信息今日大宗交易折价成交10.48万股,成交额221.05万元
Xin Lang Cai Jing· 2025-11-03 09:37
11月3日,高凌信息大宗交易成交10.48万股,成交额221.05万元,占当日总成交额的5.96%,成交价21.1 元,较市场收盘价24.83元折价15.02%。 | 及景德国日记 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券高稼 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 奥出营业部 是否为专场 | | 025-11-03 | 赢凌信息 | 688175 | 21.1 221.05 | 10.48 | 출발출장샵출장샵 | ко 葡萄糖果 | ...
珠海高凌信息科技股份有限公司 2025年第三季度报告
Zheng Quan Ri Bao· 2025-10-24 23:08
Core Viewpoint - The company reported a reversal of bad debt provisions amounting to 10.35 million yuan and recognized an asset impairment provision of 495,700 yuan for the third quarter of 2025, resulting in an overall profit increase of 9.8551 million yuan for the quarter [7][9]. Financial Data - The financial statements for the third quarter of 2025 were not audited, and the company has provided key financial data including the reversal of bad debt provisions and the recognition of asset impairment provisions [3][9]. - The company conducted a comprehensive review and impairment testing of its assets as of September 30, 2025, in accordance with accounting standards [7][8]. Shareholder Information - The company provided details on its major shareholders, including the total number of ordinary shareholders and changes in the top ten shareholders [4]. Investor Communication - An earnings briefing is scheduled for November 3, 2025, to discuss the company's performance and strategy, allowing investors to submit questions in advance [12][14][15].
高凌信息(688175.SH):前三季度净亏损3249.19万元
Ge Long Hui A P P· 2025-10-24 12:31
Core Viewpoint - Gao Ling Information (688175.SH) reported a year-on-year revenue increase of 10.88% for the first three quarters of 2025, reaching 131 million yuan, while the net profit attributable to shareholders was a loss of 32.49 million yuan, a reduction in loss of 587,400 yuan compared to the same period last year, with basic earnings per share at -0.25 yuan [1] Financial Performance - Total operating revenue for the first three quarters of 2025 was 131 million yuan, reflecting a year-on-year growth of 10.88% [1] - The net profit attributable to the parent company's shareholders was -32.49 million yuan, indicating a decrease in loss by 587,400 yuan compared to the previous year [1] - Basic earnings per share stood at -0.25 yuan [1]
高凌信息:关于2025年第三季度计提及转回资产减值准备的公告
(编辑 任世碧) 证券日报网讯 10月24日晚间,高凌信息发布公告称,公司为了更加真实、准确、客观地反映公司截至 2025年9月30日的财务状况、资产价值及经营成果,基于谨慎性原则,公司根据《企业会计准则》及 《上海证券交易所科创板股票上市规则》等相关规定,对合并报表范围内的各类资产进行了全面检查和 减值测试,根据测试结果,转回以往已计提的坏账准备1,035.08万元,并对可能发生减值损失的资产 计提资产减值准备49.57万元。 ...
高凌信息:2025年前三季度净利润约-3249万元
Mei Ri Jing Ji Xin Wen· 2025-10-24 10:16
Group 1 - The core viewpoint of the news is that Gao Ling Information reported its Q3 performance, showing a revenue increase but a net loss for the period [1] - For the first three quarters of 2025, the company's revenue was approximately 131 million yuan, representing a year-on-year increase of 10.88% [1] - The net profit attributable to shareholders was a loss of approximately 32.49 million yuan, with basic earnings per share reflecting a loss of 0.25 yuan [1] Group 2 - As of the report, Gao Ling Information has a market capitalization of 3.1 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, amounting to 80 billion US dollars this year [2] - There is a contrast in the biopharmaceutical market, where the secondary market is thriving while the primary market is experiencing a fundraising slowdown [2]
高凌信息(688175) - 关于2025年第三季度计提及转回资产减值准备的公告
2025-10-24 10:01
证券代码:688175 证券简称:高凌信息 公告编号:2025-067 单位:元 珠海高凌信息科技股份有限公司 关于 2025 年第三季度计提及转回资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 珠海高凌信息科技股份有限公司(以下简称"公司")为了更加真实、准确、 客观地反映公司截至 2025 年 9 月 30 日的财务状况、资产价值及经营成果,基于 谨慎性原则,公司根据《企业会计准则》及《上海证券交易所科创板股票上市规 则》等相关规定,对合并报表范围内的各类资产进行了全面检查和减值测试,根 据测试结果,转回以往已计提的坏账准备 1,035.08 万元,并对可能发生减值损失 的资产计提资产减值准备 49.57 万元。具体情况如下: 一、本次计提及转回资产减值准备情况概述 2025 年第三季度,公司转回坏账准备 1,035.08 万元,计提资产减值准备 49.57 万元,明细如下: | 项目/资产名称 | 年第三季度计提(转回)资产减值 2025 准备金额 | | | --- | --- | --- | ...
高凌信息(688175) - 关于举办2025年第三季度业绩说明会预告公告
2025-10-24 10:01
证券代码:688175 证券简称:高凌信息 公告编号:2025-068 2025年第三季度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、说明会类型 珠海高凌信息科技股份有限公司(以下简称"公司")已于 2025 年 10 月 25 日在上海证券交易所网站(www.sse.com.cn)披露了《2025 年第三季度报告》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况,公司定 于 2025 年 11 月 3 日(星期一)15:00-16:00 在"价值在线"(www.ir-online.cn) 举办 2025 年第三季度业绩说明会,与投资者进行沟通和交流,广泛听取投资者 会议召开时间:2025 年 11 月 3 日(星期一)15:00-16:00 会议召开地点:价值在线(www.ir-online.cn) 会议召开方式:网络互动方式 会 议 问 题 征 集 : 投 资 者 可 于 2025 年 11 月 3 日 前 访 问 网 址 https://eseb.cn/1sB ...
高凌信息(688175) - 2025 Q3 - 季度财报
2025-10-24 09:55
Financial Performance - The company's operating revenue for Q3 2025 was ¥35,590,281.25, representing a slight increase of 0.05% compared to the same period last year[3]. - The total profit for the period was a loss of ¥2,931,026.68, a significant decrease of 79.92% year-on-year[3]. - Net profit attributable to shareholders was ¥577,328.00, showing a substantial increase of 105.46% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥7,664,811.42, a decrease of 62.73% year-on-year[3]. - The basic earnings per share for the period was ¥0.01, an increase of 112.29% year-on-year[3]. - Net profit for the first three quarters of 2025 was a loss of ¥32,547,744.44, slightly improved from a loss of ¥33,161,952.63 in the same period of 2024[19]. - The company reported a basic and diluted earnings per share of -¥0.25 for both 2025 and 2024[20]. Cash Flow - The net cash flow from operating activities for the year-to-date was a negative ¥49,746,154.09, reflecting a decrease of 53.85% compared to the previous year[3]. - Cash inflows from operating activities totaled ¥192,247,663.14, up from ¥155,269,802.83 in the previous year, marking an increase of 23.8%[20]. - Cash outflows from operating activities decreased to ¥241,993,817.23 from ¥263,051,847.53, a reduction of 8.0%[20]. - The net cash flow from operating activities was -$49.75 million, compared to -$107.78 million in the previous period, showing an improvement[21]. - The net cash flow from investing activities was -$39.33 million, an improvement from -$112.97 million year-over-year[21]. - The net cash flow from financing activities was -$13.03 million, compared to -$19.97 million in the previous period, indicating a reduction in cash outflow[21]. - The company reported a net decrease in cash and cash equivalents of -$102.11 million, compared to -$240.72 million in the previous period[21]. Assets and Liabilities - Total assets at the end of the period were ¥1,897,749,818.01, a decrease of 3.54% from the end of the previous year[4]. - The equity attributable to shareholders was ¥1,740,254,323.57, down by 2.49% compared to the previous year[4]. - As of September 30, 2025, total current assets amounted to RMB 1,268,145,797.32, a decrease from RMB 1,589,080,075.66 as of December 31, 2024[13]. - The company reported a total asset value of RMB 1,897,749,818.01, down from RMB 1,967,381,335.87[14]. - The company's total liabilities decreased to ¥158,685,014.85 from ¥183,753,198.27, a decline of 13.6%[18]. - Total liabilities include accounts payable of RMB 56,645,065.03, down from RMB 68,947,033.87[14]. Research and Development - Research and development expenses totaled ¥17,950,222.99, a decrease of 17.71% compared to the same period last year[4]. - The ratio of R&D expenses to operating revenue was 50.44%, down by 10.89 percentage points year-on-year[4]. - The company reported a significant reduction in research and development expenses to ¥47,907,223.19 from ¥59,184,815.64, a decrease of 19.1%[18]. Inventory and Assets Management - The company’s inventory increased to RMB 137,009,618.10 from RMB 127,476,542.62[13]. - The company holds trading financial assets valued at RMB 737,644,865.76, down from RMB 931,797,827.94[13]. - The company’s non-current assets totaled RMB 629,604,020.69, an increase from RMB 378,301,260.21[14]. - The company has no short-term borrowings reported as of the latest financial statement[14]. Other Information - The company has no significant changes in major shareholders or their holdings reported during the period[12]. - Other income for the first three quarters of 2025 was reported at ¥4,036,705.61, down from ¥15,195,075.74 in the same period of 2024[18]. - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[22].